FDA premarket approval records identify Ferring Pharmaceuticals, Inc. as the applicant behind P010029, first approved on December 3, 2004 for NUFLEXXA (1% sodium hyaluronate), a three-injection regimen. The same PMA number carries later supplements, including a 2026 30-day notice for a new working cell bank. The records describe a single device family rather than a broad device portfolio, and the applicant name is the only corporate identity the filings establish. [2][7][1]

The approved device and its stated indication

The original approval order describes the device as indicated for treatment of pain in osteoarthritis of the knee in patients who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen. The record lists the generic name as acid, hyaluronic, intraarticular, device class 3, product code MOZ, with the Orthopedic advisory committee. The applicant address on the filing is in Parsippany, New Jersey. [2]

A later FDA summary of safety and effectiveness data for supplement P010029/S008 states that the original P010029 application for Nuflexxa was approved on December 3, 2004 and describes that device as a three injection regimen. The same document records CDRH issuing an approval order for S008 on October 11, 2011, and notes the applicant's manufacturing facility was not needed to be inspected because the already approved device was used and found in compliance with the Quality System regulation. [7]

Manufacturing supplement decided in 2026

Supplement S043 was received on August 4, 2026 and decided on September 2, 2026 under decision code OK30, a 30-Day Notice. The supplement reason is recorded as a process change affecting manufacturer, sterilizer, packager or supplier, and the approval order statement identifies the introduction of a new Working Cell Bank designated WC18-16072025. The trade name on that record is EUFLEXXA (1% sodium hyaluronate), and the expedited review flag is No. [1]

The FDA PMA database page for P010029 lists S043 among the supplements linked to the application and shows a page update date of November 2, 2026. That page also links product code MOZ to the classification database and P010029 to related records, which is how the supplement and the original approval are connected to one application number. [3]

What the collection shows and what it does not

The linked collection contains two PMA records as of the snapshot date: one OK30 decision and one APPR decision. The smaller record sample of two entries carries the same split, one OK30 and one APPR, and those counts describe only the records retrieved, not total company filings, sales or safety performance. No recall records appear in the retrieved sample. [1][2]

The manufacturer's healthcare professional site presents EUFLEXXA as a hyaluronic acid injection for osteoarthritis knee pain and describes mechanical and physiologic effects, with links to full prescribing information and safety information. Those product claims originate with the manufacturer's published documentation, not with the FDA filing records, and the site is directed at US healthcare professionals. [8]

Reading the applicant identity

Ferring Pharmaceuticals, Inc. appears as the applicant on both the 2004 approval and the 2026 supplement, and the SSED for S008 gives the applicant address as 4 Gatehall Drive, Parsippany, New Jersey. Filing addresses in these records are not evidence of a corporate headquarters, and the documents do not establish parent companies, ownership or brand relationships beyond the applicant name and the EUFLEXXA and NUFLEXXA trade names. [2][1][7]